Jubilant Therapeutics, The Wistar Institute to collaborate on COVID-19 research
To evaluate the activity of novel PAD4 inhibitors to reduce clinical severity of COVID-19
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.